Literature DB >> 17380444

Rituximab alone was effective for the treatment of a diffuse large B-cell lymphoma associated with hemophagocytic syndrome.

Takeshi Sano1, Hisashi Sakai, Kengo Takimoto, Hitoshi Ohno.   

Abstract

We report here the case of a 63-year-old man who had a diffuse large B-cell lymphoma associated with hemophagocytic syndrome (HPS). The lymphoma involved the spleen, bilateral adrenal glands, and paraaortic lymph nodes of the abdomen. In both the bone marrow and lymph nodes, hemophagocytosis was evident, and the laboratory findings were consistent with HPS. The lymphoma cells showed a CD4+, CD5+, CD10-, CD19+, CD20+, CD25+ and surface immunoglobulin microalpha/kappa+ immunophenotype. The patient was unintentionally treated with rituximab alone, resulting in complete resolution of the lymphomatous lesions as well as the features of HPS in response to the initial two doses of rituximab, although he developed gastric hemorrhage requiring vigorous resuscitation. After the completion of eight doses of rituximab, the patient remains free of disease with an excellent performance status.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17380444     DOI: 10.1007/s10147-006-0627-9

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  13 in total

1.  B-cell lymphoma-associated hemophagocytic syndrome.

Authors:  C Shimazaki; T Inaba; M Nakagawa
Journal:  Leuk Lymphoma       Date:  2000-06

2.  De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.

Authors:  Motoko Yamaguchi; Masao Seto; Masataka Okamoto; Ryo Ichinohasama; Naoya Nakamura; Tadashi Yoshino; Junji Suzumiya; Takuhei Murase; Ikuo Miura; Takashi Akasaka; Jun-ichi Tamaru; Ritsuro Suzuki; Yoshitoyo Kagami; Masami Hirano; Yasuo Morishima; Ryuzo Ueda; Hiroshi Shiku; Shigeo Nakamura
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

Authors:  J M Vose; B K Link; M L Grossbard; M Czuczman; A Grillo-Lopez; P Gilman; A Lowe; L A Kunkel; R I Fisher
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

Review 4.  Malignant histiocytosis-like B-cell lymphoma, a distinct pathologic variant of intravascular lymphomatosis: a report of five cases and review of the literature.

Authors:  T Murase; S Nakamura; K Tashiro; T Suchi; J Hiraga; N Hayasaki; M Kimura; M Murakami; Y Mizoguchi; T Suzuki; H Saito
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

5.  Intravascular large B-cell lymphoma: the CD5 antigen is expressed by a subset of cases.

Authors:  H S Khalidi; R K Brynes; P Browne; C H Koo; H Battifora; L J Medeiros
Journal:  Mod Pathol       Date:  1998-10       Impact factor: 7.842

6.  Japanese multicenter phase II and pharmacokinetic study of rituximab in relapsed or refractory patients with aggressive B-cell lymphoma.

Authors:  K Tobinai; T Igarashi; K Itoh; Y Kobayashi; M Taniwaki; M Ogura; T Kinoshita; T Hotta; K Aikawa; K Tsushita; A Hiraoka; Y Matsuno; S Nakamura; S Mori; Y Ohashi
Journal:  Ann Oncol       Date:  2004-05       Impact factor: 32.976

7.  Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy.

Authors:  L E van der Kolk; A J Grillo-López; J W Baars; M H J van Oers
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

8.  Conservative management of gastric lymphoma: the treatment option of choice.

Authors:  Wolf-Peter Schmidt; Norbert Schmitz; Ruth Sonnen
Journal:  Leuk Lymphoma       Date:  2004-09

9.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

Authors:  D G Maloney; T M Liles; D K Czerwinski; C Waldichuk; J Rosenberg; A Grillo-Lopez; R Levy
Journal:  Blood       Date:  1994-10-15       Impact factor: 22.113

Review 10.  Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan.

Authors:  Kensei Tobinai
Journal:  Int J Hematol       Date:  2002-12       Impact factor: 2.319

View more
  5 in total

1.  Alternative therapy for epstein-barr virus related hemophagocytic lymphohistiocytosis.

Authors:  Omar Al Asad; Amir Salam; Siva Mannem; Mary Ninan; Avi Markowitz; Bagi Jana
Journal:  Case Rep Oncol Med       Date:  2015-02-08

2.  An unusual case of primary hepatic lymphoma with dramatic but unsustained response to bendamustine plus rituximab and literature review.

Authors:  Sih-Han Liao; Yin-Kai Chen; Shan-Chi Yu; Ming-Shiang Wu; Hsiu-Po Wang; Ping-Huei Tseng
Journal:  SAGE Open Med Case Rep       Date:  2017-05-26

Review 3.  Infections associated with haemophagocytic syndrome.

Authors:  Nadine G Rouphael; Naasha J Talati; Camille Vaughan; Kelly Cunningham; Roger Moreira; Carolyn Gould
Journal:  Lancet Infect Dis       Date:  2007-12       Impact factor: 25.071

4.  Hemophagocytic lymphohistiocytosis as an onset of diffuse large B-cell lymphoma: A case report.

Authors:  Yueqing Cao; Lang Zou; Hao Zhou; Gan Fu; Xielan Zhao
Journal:  Oncol Lett       Date:  2022-07-05       Impact factor: 3.111

Review 5.  An update on renal involvement in hemophagocytic syndrome (macrophage activation syndrome).

Authors:  Haydarali Esmaili; Elmira Mostafidi; Bahareh Mehramuz; Mohammadreza Ardalan; Mohammadali Mohajel-Shoja
Journal:  J Nephropathol       Date:  2015-07-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.